Feature|Videos|August 5, 2026
The Evolving Bioconjugate Landscape
Key Takeaways
- Identify how conjugation chemistry has shifted from lysine-based methods toward site-specific cysteine and glycan approaches.
- Recognize how payload diversification and rising DAR have introduced new analytical considerations.
Experts trace how the bioconjugate field has transformed since 2016 and where it is headed next.
Episodes in this series
Sponsored by Waters Corporation
As the diversity of conjugated therapeutics has grown, the field has moved beyond early lysine-based conjugation methods that produced unpredictable drug loading. Deanna Hunt, Senior Director of Business Development at KBI Biopharma traces how this challenge has been addressed since 2016, when most antibody-drug conjugate programs relied on lysine conjugation and basic measurement of drug-to-antibody ratio (DAR). The industry’s shift toward site-specific cysteine and glycan conjugation has improved control over where and how many drug molecules attach to an antibody. Even regulators are starting to shift from characterization to explaining why an attribute matters within conjugation.
Related Content
